Arthneeti
All Q1 FY27 results →
NL

Neuland Labs.

Q1 FY27Pharmaceuticals & Biotechnology

Neuland Laboratories Q1 FY27 earnings call: Revenue & Margins

Q1 FY27 earnings call: what management said on revenue, margins and capex.

Price₹22,928
Market cap₹29.9K Cr
P/E60.1
Updated25 Aug 2026
Read4 min read

The short version

Neuland aims for approximately 20% growth annually over FY27 and FY28. Neuland expects FY27 and FY28 to be years of growth, with aspirations to grow around 20% annually.

From Neuland Labs.'s Q1 FY27 earnings-call transcript · updated 25 Aug 2026.

Revenue & Sales Performance

  • Neuland aims for approximately 20% growth annually over FY27 and FY28.
  • FY27 is expected to be a good year with growth, though lumpiness and volatility due to a few key molecules will persist.
  • Commercial CMS growth is primarily driven by a handful of active molecules, with new projects adding diversity.
  • Development revenue is anticipated to increase in FY27 with new projects lined up, contributing to future commercial revenue beyond FY27.
  • Peptide manufacturing capabilities are expanding with a new facility being commissioned soon, already having order visibility and readiness for projects.

2 more points from Neuland Labs.'s call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Neuland Labs. said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • Neuland has been investing at a higher pace and scale over the last 3 years, continuing into FY27, focusing on manufacturing infrastructure, R&D, peptides, sterile APIs, and capacity expansion.
  • Recent capital expenditure in Q1FY27 was INR121.6 crores, mainly for new R&D and peptide facilities.
  • Capital investments of approx. INR203 crores were approved in the quarter, with INR196 crores earmarked for strategic growth, largely capacity expansion at Unit 1.
  • Total approved capex over 13 quarters is INR1,460 crores, with INR870 crores spent to date; the remainder is committed toward ongoing projects.
  • Future capex will be significantly higher in quantum compared to past investments and will qualitatively differ by targeting newer, more complex modalities and potential geographic diversification.

2 more points from Neuland Labs.'s call on capex

Create a free account to keep reading this call

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
1KRM Ayurveda
Rev 1Mar 1
2Accretion Pha.
Rev 1Mar 2
3
Rev 1Mar 3
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Neuland Labs. said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

  • Neuland Laboratories Limited typically has good visibility of at least a 6-month order book as a CDMO.
  • The company is cautious about fully revealing exact order book details or expected yearly performance.
  • They aspire to achieve about 20% growth over FY27 and FY28 but avoid giving firm guidance.
  • As per Saharsh Davuluri, order visibility is consistent with expectations and factors in any destocking or stocking risks.
  • No abrupt surprises from destocking are expected during FY27.

2 more points from Neuland Labs.'s call on order book

Create a free account to keep reading this call

Neuland Labs. — Quarterly revenue & net profit

Revenue Net profit
Dec 2024Q3 FY25
Mar 2025Q4 FY25
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26

Q1 FY27 figures are not in this chart yet. Latest shown: Mar 2026 (Q4 FY26). The Q1 FY27 numbers from the filing are in the analysis on this page.

Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹776 Cr, net profit ₹213 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Continue your research

What Neuland Labs.'s management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

  • KRM Ayurveda (Q1 FY27)

    Total income for Q1 FY27: ₹3,286.55 Lakhs, +32.4% YoY . Key investor presentation takeaways from KRM Ayurveda Ltd's Q1 FY27 investor presentation — and how it r

  • Balaxi Pharma (Q1 FY27)

    Q1 FY27 Revenue: ₹80.68 crore, up 14.1% YoY from ₹70.74 crore in Q1 FY26 (Page 20). Key investor presentation takeaways from Balaxi Pharma's Q1 FY27 investor pr

  • Sanjiv.Parant. (Q1 FY27)

    Q1 FY27 consolidated revenue from operations: ₹238.39 Mn, up 33.8% YoY from ₹178.92 Mn in Q1 FY26 (Page 25). Key investor presentation takeaways from Sanjivani

  • Natural Capsules (Q1 FY27)

    Revenue from Operations for Q1FY27: ₹48.71 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q1 FY27 investor presentation — and how it ra

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Torrent Pharma.

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Neuland Labs. and 15K+ more earnings calls,
for less than your morning chai

a day

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Neuland Labs. Q1 FY27 results?

Neuland aims for approximately 20% growth annually over FY27 and FY28. Neuland expects FY27 and FY28 to be years of growth, with aspirations to grow around 20% annually.

What is Neuland Labs. share price analysis?

Neuland Labs. currently shows a neutral. The stock trades at a P/E of 60.1 with a market cap of ₹29,895 Cr. Investors should review the full earnings analysis for detailed insights.

Is Neuland Labs. planning capital expenditure?

Neuland has been investing at a higher pace and scale over the last 3 years, continuing into FY27, focusing on manufacturing infrastructure, R&D, peptides, sterile APIs, and capacity expansion. - Recent capital expenditure in Q1FY27 was INR121.6 crores, mainly for new R&D and peptide facilities. - Capital investments of approx.

Keep Neuland Labs. on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.